Clinical Trials Directory

Trials / Completed

CompletedNCT00832455

Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)

A 12 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Montelukast Sodium (Singulair®), 4 or 5 mg/Day in Pediatric Subjects With Uncontrolled Asthma

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
445 (actual)
Sponsor
Organon and Co · Industry
Sex
All
Age
2 Years – 14 Years
Healthy volunteers
Not accepted

Summary

a study to describe patient and physician satisfaction with montelukast therapy for the control of asthma used either as monotherapy or in combination with inhaled corticosteroids

Conditions

Interventions

TypeNameDescription
DRUGmontelukast sodiumMontelukast 4-5 mg for 12 weeks, oral tablet

Timeline

Start date
2006-06-01
Primary completion
2008-10-01
Completion
2008-10-01
First posted
2009-01-30
Last updated
2024-05-13
Results posted
2010-02-05

Source: ClinicalTrials.gov record NCT00832455. Inclusion in this directory is not an endorsement.

Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolle (NCT00832455) · Clinical Trials Directory